Q4 & FY22 Highlights

Q4 FY22 Snapshot 12.7% INR 485.5 Cr Revenues 12.2% INR 419.7 Cr Non Covid Revenues Margin 13.2% 6.7 Mn 26.9% INR 130.7 Cr Patients Normalised EBITDA* 8.0% 16.3 Mn Margin INR 72.9 Cr 15.0% Samples Normalised PAT** *Normalised EBITDA excl. RSU, CSR **Normalised PAT excl. notional depreciation on consolidation of Suburban Note: Results includes Suburban Diagnostics 25 25 Dr Lal PathLabs

View entire presentation